In the news release, Canadian Investment Regulatory Organization Trading Halt - MUSL, issued 08-May-2025 by Canadian Investment Regulatory Organization (CIRO) - Halts/Resumptions over CNW, we are advised by the company that the "All Issues" section should read "Yes." The complete, corrected release follows:

VANCOUVER, BC, May 8, 2025 /CNW/ - The following issues have been halted by CIRO:

Company: Promino Nutritional Sciences Inc

BURLINGTON, ON, Nov. 13, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") announces it has added three new distribution partners to expand North American distribution of its patented essential amino acid products Rejuvenate Muscle Activator™ and Promino™ - NSF Certified for Sport®.

BURLINGTON, ON, Nov. 5, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") today announced Initial product  orders from Vigor Nation to distribution Rejuvenate™ and Promino™ across the Caribbean region, reaching millions of potential active nutrition supplement consumers. Furthermore, the Company has entered into a letter of intent with Altanzaan LLC, one of the largest sports nutrition distributors in Mongolia, to make Rejuvenate and Promino available to millions of consumers in the East Asian country.

BURLINGTON, ON, Oct. 29, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") announces it has added Netrition.com as a distribution partner to provide Rejuvenate Muscle Activator™ to health and wellness consumers globally.

BURLINGTON, ON, Sept. 18, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") has announced the commencement of the preclinical trial to demonstrate the effectiveness of the Promino™ patented IP for the retention of muscle mass in cancer patients undergoing aggressive chemotherapy treatment. The preclinical trial will be led by Dr. Patrick Gunning, who was appointed as special advisor to the Company on May 8, 2024 to conduct these trials.

BURLINGTON, ON, Sept. 11, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") has reached an agreement with the licensor of the patented muscle health blend (the "Patent") used in the Company's Rejuvenate Muscle Activator™ and Promino™ products on an exclusive international rights provision for the RTD market, and strengthens the current terms for the powdered supplement business. Under the terms of the agreement dated September 5, 2024, Promino must invest US$1 million to support production and marketing of the RTD launch by March 5, 2025.

BURLINGTON, ON, Sept. 4, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") today highlights the Company's continued progress in its plan to increase revenue and expand consumer acceptance of its patented functional beverage brands.

BURLINGTON, ON, Aug. 26, 2024 /CNW/ - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") announces today that iHerb has listed its Promino™ and Rejuvenate Muscle Activator™ brands.